

IMSUT Hospital

Department of Pharmacy

薬剤部

Director	Seiichiro Kuroda
Chief	Yohei Iimura
Chief	Sonoe Minegishi-Higashino
Pharmacist	Masaaki Ishibashi
Pharmacist	Mika Yamamura-Noguchi
Pharmacist	Mai Yokota

薬剤部長	黒田	誠一郎
薬剤主任	飯村	洋平
薬剤主任	峰岸	園恵
薬剤師	石橋	正祥
薬剤師	山村	実佳
薬剤師	横田	舞

The Department of Pharmacy seeks to provide high-quality pharmaceutical care services. We contribute to the team approach to patient-oriented medical care and provides a drug distribution service. We are also trying to contribute to propel the right use of medicines for patients.

- Clinical trial for cancer supportive care led by pharmacist

We are working on phase III study regarding to prevention of capecitabine-induced hand-foot syndrome (HFS). This project is supported by a Practical Research for Innovative Cancer Control project grant (No. 24ck0106978h0001 J-SUPPORT2401/JORTC-SUP06 (J-DIRECT): a randomized, double blind, placebo-controlled Phase III study evaluating preventive effect of diclofenac cream for capecitabine related hand foot syndrome) from the Japan Agency for Medical Research (AMED). Primary investigator is Yohei Iimura. This trial is based on our phase II study (T-CRACC study, BMC Gastroenterol. 2022;22:341.). New evidence will be published in 2025 from our pharmacy.

- Collaboration with MASCC

Yohei Iimura is the member of Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group. Skin toxicity guideline project is ongoing. MASCC guideline regarding to EGFR-I related skin toxicity and hand-foot syn-

drome and nail toxicity guideline will be published in 2025.

- Skin toxicity guideline project with JASCC

Yohei Iimura is the board member of Japanese Association of Supportive Care in Cancer (JASCC) Oncodermatology Study Group. Skin toxicity guideline project for Asian countries is ongoing. Several review regarding to skin toxicity for Asia will be published in 2025.

- Observational study


Two following prospective observational study are ongoing.

-Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team for gastrointestinal cancer chemotherapy: prospective observational study; M-CAST study (BMC Gastroenterol. 2023;23:215.)


-A prospective observational study to evaluate the efficacy of fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in patients receiving platinum- based chemotherapy (LODEC-N) (J Clin Trials. 13:532.)

Mechanism of developing HFS

- (i) Inhibition of the proliferation of skin basal cells
- (ii) Secretion of drugs from the eccrine sweat glands
- (iii) Involvement of drug degradation products
- (iv) An inflammatory response caused by IL-1a, IL-1b, IL-6, and reactive oxygen species



Preventive Effect of Diclofenac Topical for Capecitabine Related Hand Foot Syndrome a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial: J-SUPPORT2401/JORTC-SUP06



Publications

- Iimura et al. A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT). *Int J Clin Oncol.* 2025 Aug; 30 (8): 1553-1561. doi: 10.1007/s10147-025-02789-z. Epub 2025 May 14.
- Iimura et al. A phase II study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). *Int J Clin Oncol.* 2025 Nov; 30(11): 2316-2324. doi: 10.1007/s10147-025-02857-4. Epub 2025 Aug 14.
- Iimura et al. Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic ap-

- proaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team. *Int J Clin Oncol.* 2025 Nov; 30 (11): 2192-2207. doi: 10.1007/s10147-025-02868-1. Epub 2025 Sep 1.
- Iimura et al. A Literature Review and Management Approach for Severe Skin Toxicity Induced by Enfortumab Vedotin Through Sequential Adaptation and Combination With Immune Checkpoint Inhibitors. *Cureus.* 2025 Aug 9;17(8):e89678. doi: 10.7759/cureus.89678. eCollection 2025 Aug.
- Iimura et al. Chemotherapy-related hand-foot syndrome and hand-foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study team. *Int J Clin Oncol.* 2025 Dec; 30(12): 2474-2488. doi: 10.1007/s10147-025-02895-y. Epub 2025 Oct 6.